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Acute kidney injury causes great morbidity and mortality in both the community and hospital
settings. Understanding the etiological factors and the pathophysiological principles resulting in
acute kidney injury is essential in prompting appropriate therapies. Recently hyperuricemia has
been recognized as a potentially modiﬁable risk factor for acute kidney injury, including that
associated with cardiovascular surgery, radiocontrast administration, rhabdomyolysis, and6.09.006
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Heat stress nephropathyPlease cite this article in press as: Hahn K et al., Serumassociated with heat stress. This review discussed the evidence that repeated episodes of acute
kidney injury from heat stress and dehydration may also underlie the pathogenesis of the
chronic kidney disease epidemic that is occurring in Central America (Mesoamerican nephropa-
thy). Potential mechanisms for how uric acid might contribute to acute kidney injury are also
discussed, including systemic effects on renal microvasculature and hemodynamics, and local
crystalline and noncrystalline effects on the renal tubules. Pilot clinical trials also show potential
beneﬁts of lowering uric acid on acute kidney injury associated with a variety of insults. In sum-
mary, there is mounting evidence that hyperuricemia may have a signiﬁcant role in the develop-
ment of acute kidney injury. Prospective, placebo controlled, randomized trials are needed to
determine the potential beneﬁt of uric acid lowering therapy on kidney and cardio-metabolic
diseases.
 2016 Production and hosting by Elsevier B.V. on behalf of Cairo University. This is an open
access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/
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Acute kidney injury (AKI) is a major cause of morbidity and
mortality worldwide in both community and hospital settings
[1,2]. There has been a major effort by the International Soci-
ety of Nephrology to reduce mortality from AKI, especially in
the rural setting (‘‘0 by 2025” initiative) [2,3]. AKI is especially
common in the intensive care unit, where it occurs in as many
as 20–30% of patients [4]. Even small rises in serum creatinine
(SCr), that do not meet the criteria for AKI, are independent
predictors of poor outcome [5]. There are numerous risk fac-
tors for AKI and the pathological mechanisms are complex
[6]. However, most researchers accept that ischemic AKI
involves loss of renal autoregulation with enhanced levels of
vasoconstrictors leading to hypoperfusion and ischemia/reper-
fusion injury [6]. Accordingly, therapeutic targets have
included intervening at various stages of this proposed
hypothesis.
Recently uric acid has been resurrected as a potential medi-
ator of AKI, with the hypothesis that this ancient biological
factor might be driving inﬂammatory pathways that might
accentuate acute injury to the kidney [7–12]. Indeed, uric acid
is now known not to be biologically inert but to have a widery: A mini review, J Adv Res (2016), http://dx.doi.org/10.1016/j.jare.2016.09.006
Uric acid and acute kidney injury 3range of actions, including being both a pro- and anti-oxidant,
a neurostimulant, and an inducer of inﬂammation and activa-
tor of the innate immune response. These effects of uric acid
may potentially explain why uric acid is associated with the
development of chronic kidney disease, as well as for hyperten-
sion, coronary artery disease, metabolic syndrome and dia-
betes [13–19].
This review summarizes the epidemiology, pathophysiol-
ogy, and clinical studies that link uric acid with AKI. Hyper-
uricemia, deﬁned as >6.5 mg/dL in women and >7 mg/dL
in men, has also been recently recognized as an independent
predictor for AKI. While the relationship of hyperuricemia
with AKI from acute tumor lysis syndrome via crystal-
dependent mechanisms is well known, there is also increasing
evidence that uric acid may modulate AKI via crystal-
independent mechanisms.
Uric acid in acute kidney injury
Crystal-dependent mechanism of AKI
The best known example of crystal-induced tubulopathy is
tumor lysis syndrome in which the pathogenesis of AKI is
thought to be mediated by the precipitation of uric acid into
crystals that obstruct the distal tubules and collecting ducts
of the kidney [20–22]. Typically this occurs when a subject with
a large tumor burden is treated with chemotherapy, especially
in subjects where the tumor is extremely sensitive to such ther-
apy such as after cytoreductive therapy for leukemia or lym-
phoma [23]. The release of DNA and RNA from the lysed
tumor cells, is metabolized in the liver, generating large
amounts of uric acid that enter the circulation. In turn, this
results in a surge in renal excretion of uric acid that exceeds sat-
uration, leading to crystallization with tubular luminal obstruc-
tion, and local granulomatous inﬂammation associated with
macrophage and T cell inﬁltration [24]. The acute lysis of tumor
cells also results in lactic acid generation that may lead to uri-
nary acidiﬁcation which enhances the crystallization of uric
acid with its precipitation that occurs primarily in the collecting
duct system and, to some extent, in the vasa recta. Uric acid
crystal deposition causes increased tubular pressure, increased
intrarenal pressure, and compressive congestion of the renal
venules, and also results in inﬂammasome-mediated activation
of the innate immune system with local inﬂammation and ﬁbro-
sis. The resulting increased renal vascular resistance and
reduced renal blood ﬂow combine with elevated tubular pres-
sure to reduce glomerular ﬁltration, culminating in AKI.
Clinical studies have also shown that preventing the devel-
opment of hyperuricemia can prevent the development of
tumor lysis syndrome. For example, in a multicenter, random-
ized, controlled trial comparing rasburicase and allopurinol in
children at high risk for tumor lysis syndrome, more effective
reduction of serum uric acid (AUC of uric acid of 128
± 70 mg/dL h in the rasburicase group vs. an AUC of uric acid
329 ± 129 mg/dL h in the allopurinol group, P< 0.0001) was
associated with a greater reduction in serum creatinine (41% vs.
11.4% in the rasburicase vs allopurinol group, P< 0.001) val-
ues [25]. Normalization of hyperuricemia with rasburicase
given preventively during induction of chemotherapy of aggres-
sive non-Hodgkin lymphoma also resulted in reduction in
serum creatinine [26,27].Please cite this article in press as: Hahn K et al., Serum uric acid and acute kidney injuClassically, the AKI in tumor lysis syndrome has been
thought to occur primarily in subjects in which the serum uric
acid rises above 12 mg/dl, and in which the urine uric acid/cre-
atinine ratio is greater than 1. As such, serum uric acid levels in
the modestly elevated range (7–12 mg/dL) have historically
thought not to be at a level that will lead to urinary crystalliza-
tion and tubular injury. Indeed, marked hyperuricemia leading
to urate crystal deposition with AKI has been shown experi-
mentally to cause AKI with a concomitant decrease in
glomerular ﬁltration rate (GFR) and renal blood ﬂow (RBF)
by micropuncture and PAH clearance studies, respectively
[28]. However, crystal-associated tubular obstruction is not
the only mechanism involved in AKI associated with tumor
lysis syndrome. Both local and systemic inﬂammatory
responses play signiﬁcant roles as demonstrated by concerted
array of cytokine responses with immunosuppression therapy
[29]. Anders et al. have shown that intracellular NLRP3
inﬂammasome, a pattern recognition platform, translates crys-
tal uptake into innate immune activation via secretion of IL-1b
and IL-18 and can trigger inﬂammation and AKI in crystal-
related disorders [30]. Cytotoxicity of the uric acid crystals
may also involve receptor-interacting protein kinase 3
(RIPK3) or mixed lineage kinase domain like (MLKL), two
core proteins of the necroptosis pathway [31]. Another exam-
ple of crystal-induced tubulopathy is rhabdomyolysis where
the high rates of generation and urinary excretion of uric acid
and low pH of tubular urine further contribute to tubular
obstruction by uric acid crystal-containing casts [32,33].
Crystal-independent mechanism of AKI
Experimental studies
A breakthrough in our understanding of the biology of hype-
ruricemia was shown by Sanchez-Lozada et al. [34], who
demonstrated in experimental models that mild hyperuricemia,
at levels that do not cause crystal formation or deposition, can
also induce a 50% reduction in GFR and RBF [18,35], open-
ing the possibility that even mild hyperuricemia may act as a
risk factor for AKI. Mild hyperuricemia has since been shown
to have proinﬂammatory and anti-angiogenic properties [36].
Uric acid causes activation of the renin-angiotensin system,
and increases reactive oxygen radicals, inﬂammatory media-
tors (MCP-1, ICAM), vascular responsiveness and vascular
smooth muscle proliferation and migration; uric acid also inhi-
bits proximal tubular cell proliferation, vascular endothelial
cell proliferation and migration and decreases bioavailability
of nitric oxide, increases preglomerular arteriolar thickening
and impairs renal autoregulation.
These proinﬂammatory effects of uric acid provide the
impetus to investigate the relative contribution of hyper-
uricemia to AKI in a model of cisplatin-induced AKI in rats.
Moderate hyperuricemia was associated with an absence of
intrarenal crystals and the occurrence of greater injury of the
pars recta (S3) segment of the proximal tubule and prolifera-
tion with signiﬁcantly greater macrophage inﬁltration and
increased expression of monocyte chemoattractant protein-1
than the control cisplatin group [37]. Treatment with urate oxi-
dase (recombinant uricase) reversed the inﬂammatory changes
and lessened tubular injury. These data provided the ﬁrst
experimental evidence that uric acid, at concentrations that
do not cause intrarenal crystal formation, may exacerbatery: A mini review, J Adv Res (2016), http://dx.doi.org/10.1016/j.jare.2016.09.006
4 K. Hahn et al.renal injury in a model of AKI. It might be speculated that the
mechanisms of hyperuricemia-induced AKI in this model
included a proinﬂammatory pathway involving chemokine
expression by tubular cells with leukocyte inﬁltration.
Epidemiological studies
Cardiac surgery
Recently our group reported that even modest hyperuricemia
increases the risk for AKI following aortic aneurysm repair
or cardiovascular surgery [38,39]. In one study, hyperuricemia
(preoperative serum uric acid >7 mg/dL) was found to confer
a 35-fold increased risk for AKI that was independent of other
risk factors including a baseline reduction in eGFR [40]. Serum
uric acid also exhibited a U-shaped relationship with AKI. A
similar relationship between serum uric acid and AKI in car-
diac surgery was reported by Joung et al. [35]. The study of
the relationship of serum uric acid and renal function, speciﬁ-
cally GFR, is hindered by the technical complexities and the
lack of broad consensus on guidelines about estimating
GFR. However, using a retooled creatinine clearance equation
with the power and versatility estimates renal function under
non-steady conditions, i.e. kinetic estimated GFR equation.
Hyperuricemia also effectively predicted subsequent changes
in urinary neutrophil gelatinase-associated lipocalin (NGAL),
serum creatinine (SCr), kinetic estimated GFR and the devel-
opment of AKI [41]. Uric acid exhibited a linear relationship
with serum creatinine and an inverse relationship with kinetic
estimated GFR in cardiac surgery patients. This supports the
proposed mechanisms of AKI that ischemic AKI involves loss
of renal autoregulation with enhanced levels of vasoconstric-
tors leading to hypoperfusion and ischemia/reperfusion injury.
Recent data in asymptomatic hyperuricemic subjects demon-
strated improvement in estimated GFR when serum uric acid
was lowered with the xanthine oxidase allopurinol [15,42,43].
Acute myeloid leukemia
Hyperuricemia may also increase the risk for other forms of
AKI as well, including from cisplatin treatment in oncology
patients where a linear relationship between serum uric acid
and serum creatinine has been demonstrated [44]. In acute
myeloid leukemia patients [32], serum uric acid has been
shown to be an independent predictor of AKI and tumor lysis
syndrome with superior predictive performance than conven-
tional markers such as lactate dehydrogenase, cytogenetic pro-
ﬁle and tumor markers. In order to conﬁrm the previously
reported relationship between uric acid and estimated GFR
in cardiac surgery patients, it is investigated the relationship
between SUA and KeGFR in a larger, unique patient cohort
wherein SUA levels ﬂuctuate during the course of standard
care. Koratala et al. retrospectively studied acute myeloid leu-
kemia patients [45]. The unique characteristic of this cohort
was that all of the patients were managed with the same clin-
ical protocols, i.e., they were admitted to the hospital with a
conﬁrmed diagnosis of AML, underwent laboratory, imaging
and cytogenetic testing, received prophylactic therapy with
bicarbonate containing ﬂuids and oral uric acid lowering med-
ications, and then received induction therapy. The investiga-
tors demonstrated a linear relationship between serum uric
acid and serum creatinine and an inverse relationship betweenPlease cite this article in press as: Hahn K et al., Serum uric acid and acute kidney injuserum creatinine and kinetic estimated GFR, validating previ-
ous ﬁndings and reinforcing the emerging translational physi-
ological evidence regarding the role of uric acid in AKI.
Radiocontrast nephropathy
Radiocontrast is well known to be a nephrotoxin, and can
result in either oliguric or anuric AKI. The injury is associated
with both renal vasoconstriction and tubular toxicity, but the
actual mechanism remains unknown. Interestingly, radiocon-
trast causes an acute uricosuria [41,46] that may potentially
play a role in injury. Indeed, an elevation in serum uric acid,
even at modest levels, is known to increase the risk for
contrast-induced AKI [47,48]. A recent meta-analysis by Kan-
bay et al. that included 10 studies reported that elevated levels
of serum uric acid were associated with a twofold increased
risk for the development of radiocontrast-induced AKI
(pooled odds ratio 2.03; 95%CI 1.48–2.78) [49]. Prophylactic
administration of allopurinol to subjects undergoing radiocon-
trast procedures was associated with signiﬁcant renoprotection
compared to hydration with or without N-acetyl cysteine
[50,51]. These studies are consistent with the hypothesis that
blocking the acute uricosuria could potentially be beneﬁcial
in this condition.
Crystal-dependent and crystal-independent mechanisms in
Mesoamerican nephropathy and heat stress nephropathy
In recent years an epidemic of chronic kidney disease has been
identiﬁed along the Paciﬁc coast of Central America where it
typically affects manual laborers working in the sugarcane or
other agricultural communities [37,44,52]. While the etiology
remains unknown, a common risk factor appears to be heat
stress and recurrent dehydration [53]. Heat stress is often asso-
ciated with mild muscle injury with subclinical rhabdomyolysis
that can lead to increase nucleotide release and a rise in serum
uric acid levels of injury [33,54]. Indeed, subclinical rhabdomy-
olysis, marked hyperuricemia, and uricosuria with crystal for-
mation have been documented in sugarcane workers
[37,44,53,55]. Indeed, it has been found that repeated heat-
stress in agricultural workers may be associated with a rise
in both serum and urine uric acid during the workday
[37,44,53], and when urinary uric acid concentrations exceed
solubility, uric acid crystals may form, causing local injury.
This suggests a potential mechanism involving repeated AKI
from intermittent hyperuricemia and uricosuria, and is consis-
tent with evidence from biomarker studies that renal injury is
likely intermittent in this condition [56,57]. Other mechanisms
could also be operative in causing renal injury in this disease,
including the effects of vasopressin or the endogenous polyol
fructokinase pathway [58–60], or from the ingestion of toxins
such as agrochemicals or heavy metals [61].
Proposed mechanisms for how uric acid may cause acute kidney
injury
The proposed mechanisms for how uric acid may induce AKI
are shown in Fig 1, and are discussed in detail below. Tradi-
tionally, the mechanism by which uric acid was posited to
cause kidney damage was via uricosuria with supersaturation
leading to intratubular crystal deposition that would then bindry: A mini review, J Adv Res (2016), http://dx.doi.org/10.1016/j.jare.2016.09.006
Fig. 1 Postulated mechanisms for uric acid induced acute kidney injury.
Uric acid and acute kidney injury 5to tubular cells via toll-like receptors to initiate innate immune
response with activation of inﬂammasomes and a local inﬂam-
matory response. There is increasing thought that acute rises in
serum uric acid, such as might occur with heat stress, rhab-
domyolysis or with radiocontrast administration may lead to
urinary levels that may cause renal injury. This might be espe-
cially common in the setting where the urine is concentration
and acidic, such as in subjects with dehydration, as an acidic
urinary pH favors crystal formation [62,63]. In this regard,
transient hyperuricosuria is not uncommon in healthy men,
and in serial determinations may occur approximately 20%
of the time [64]. While most attention has focused on the
effects of urate crystalluria as a nephrotoxin [65,66], uricosuria
in the absence of crystalluria may also affect tubular function
[67–70] by inducing oxidative stress, epithelial-mesenchymal
transformation and tubular production of chemotactic factors,
and by altering cell proliferation [67,68,70–72].
Generation of uric acid within tubular cells may also induce
inﬂammatory changes. For example, the metabolism of fruc-
tose by fructokinase in the proximal tubular cells generates
uric acid that may induce local injury and inﬂammation [72].
Chronic dehydration, by activating the aldose reductase sys-
tem, can also cause local generation of fructose that is metab-
olized to uric acid [58]. Perioperative ischemia-reperfusion
injury of the S3 segment of the proximal tubule, as well as of
the medullary thick ascending limb in the outer medulla [73],
have been shown to deplete intracellular ATP; this results in
uric acid production that could participate in multiple patho-
physiological events including tubular cell injury, free radical
generation, tight junction and cytoskeletal disruption, and ulti-
mately loss of apical-basolateral polarity [74].
In a related important development, the United States Fed-
eral Drug Administration has strengthened the existing warn-
ing about the risk of AKI in patients taking sodium-glucose
cotransporter 2 (SGLT2) inhibitors. These drugs block glucosePlease cite this article in press as: Hahn K et al., Serum uric acid and acute kidney injuuptake in the S1 and S2 segments of the proximal tubular, and
hence increase glucose delivery to the S3 segment. Recently
investigators have shown that conditions associated with
hyperglycemia and/or hyperosmolarity may result in the
induction of aldose reductase in the proximal tubule, which
can convert glucose to sorbitol with subsequent conversion
to fructose by sorbitol dehydrogenase [58,75]. In turn, the gen-
eration of fructose in the S3 segment can lead to local uric acid
generation, oxidative stress, release of chemokines, and tubu-
lar injury [72,76]. Reducing uric acid can ameliorate the oxida-
tive stress and chemokine release [72]. Thus it seems likely, that
despite numerous potential beneﬁts of SGLT2 inhibitors [77],
they may increase the risk for AKI, especially under conditions
in which hyperglycemia or hyperosmolarity is present.
While local effects of uric acid on the kidney are likely, sys-
temic hyperuricemia has also been strongly linked with sys-
temic inﬂammation, oxidative stress, endothelial dysfunction
and activation of the renin-angiotensin system, and some stud-
ies suggest these effects may be improved by lowering uric acid
with allopurinol [78–81]. In cell culture systems, soluble uric
acid has been found to stimulate chemotactic factors, vasocon-
strictive mediators (such as thromboxane and endothelin),
growth factors, and prooxidants, and to decrease the bioavail-
ability of nitric oxide [82–86]. Uric acid can also function as an
antioxidant [87], but the reaction of uric acid with oxidants can
also generate new free radicals and alkylating agents [88]. In
animals, the primary effect of hyperuricemia on the kidney
appears to be a reduction in renal blood ﬂow and an increase
in glomerular pressure that can be prevented by lowering uric
acid and/or blocking oxidative stress [34,89]. The fundamental
changes in renal vasculature and vasoconstrictive mechanisms
that occur in AKI are similar to those observed with hyper-
uricemia, including renin-angiotensin-aldosterone system acti-
vation, oxidative stress, reduction of nitric oxide and
inﬂammation.ry: A mini review, J Adv Res (2016), http://dx.doi.org/10.1016/j.jare.2016.09.006
Table 1 Clinical trials of the effect of uric acid in acute kidney injury (AKI) and chronic kidney disease (CKD). source:
www.clinicaltrials.gov.
Study type
Lowering Serum Uric Acid to Prevent Acute Kidney Injury Interventional
Predicting Acute Kidney Injury After Coronary Artery Bypass Graft Observational
Chronic kidney diseases
Uric acid and the endothelium in CKD Interventional
Uric acid and long-term outcomes in chronic kidney disease Observational
The eﬀect of uric acid decrement on endothelial function in patients with chronic renal failure Observational
FFT, inﬂammation, lipid metabolism, blood pressure and organ damage in patients with chronic kidney disease Observational
The eﬀect of uric acid lowering in Type I diabetes Interventional
A multicenter trial of allopurinol to prevent kidney function loss in Type I diabetes Interventional
A controlled study of uric acid on the progression of IgA nephropathy Interventional
6 K. Hahn et al.Clinical evidence for protection in AKI
The most relevant clinical question is whether treatment of
hyperuricemia will decrease the risk of subsequent AKI and
translate into clinical beneﬁts in terms of prevention or a better
outcome of CKD and cardiovascular disease. Two small stud-
ies reported that lowering serum uric acid with allopurinol pre-
vents development of radiocontrast induced AKI [50,51].
Kanbay et al. were able to show that treatment with allopuri-
nol resulted in an increase of eGFR in asymptomatic hyper-
uricemic subjects [42] while another study by Tallaat and El-
Sheikh reported a deterioration of kidney function after with-
drawal of allopurinol in CKD 3 and 4 patients [90]. In the
FOCUS study, treatment with febuxostat improved renal
function in subjects with chronic kidney disease, with a reduc-
tion of serum uric acid by 1 mg/dL predicting an improvement
of 1 mL/min in estimated GFR [91]. Finally, in a pilot study by
Ejaz et al., preoperative treatment of hyperuricemia with ras-
buricase in subjects undergoing cardiovascular surgery
resulted in a decrease in incidence of AKI (7.7% vs. 30.8%),
that, while not reaching signiﬁcance, is consistent with a poten-
tial beneﬁt of lowering uric acid to reduce the risk for AKI
[92].
Limitations
There are some ﬁndings that challenge the hypothesis that uric
acid may have a role in AKI. First, most of the clinical studies
have involved small numbers of patients, and hence random-
ized, placebo-controlled, double-blind studies are indicated.
Second, there are also studies suggesting that uric acid may
be a biomarker for xanthine oxidase activity, and it is the xan-
thine oxidase that is driving the disease through its ability to
produce oxidants [93,94]. Indeed, some authors believe soluble
uric acid may be beneﬁcial as it can function as an antioxidant
[87,94]. However, the reaction of uric acid with peroxynitrite
generates radicals and alkylating species [88,95,96]. Several
large genetic studies also could not link genetic polymorphisms
that raise uric acid with hypertension or diabetes [97,98], while
others have found such associations [99–102].
Conclusions
In summary, there is mounting evidence that uric acid is a
potential causative agent in AKI. Indeed, a large retrospectivePlease cite this article in press as: Hahn K et al., Serum uric acid and acute kidney injustudy of hospitalized patients with cardiovascular, hematol-
ogy/oncology, infectious disease, gastrointestinal and respira-
tory disorders, recently reported a linear relationship
between serum uric acid level and the development of
dialysis-dependent AKI during hospitalization (odds ratio
for SUA> 9.4 mg/dL was 1.79; CI = 1.13–2.82) [103]. Uric
acid may increase the risk for AKI via both systemic effects
of hyperuricemia and local effects due to crystalline and non-
crystalline effects of urinary uric acid on tubules. Given the
laudable goal for reducing mortality from AKI, more studies
are needed to assess whether lowering uric acid can prevent
or treat AKI. Indeed, a variety of studies are underway
(Table 1).
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